Mechanisms of chemotherapy resistance in ovarian cancer  

作　　者：Mylena Ortiz Emma Wabel Kerry Mitchell Sachi Horibata 

机构地区：[1]Precision Health Program,Michigan State University,766 Service Road,East Lansing,MI 48824,USA. [2]Department of Pharmacology and Toxicology,College of Human Medicine,Michigan State University,East Lansing,MI 48824,USA.

出　　处：《Cancer Drug Resistance》2022年第2期304-316,共13页癌症耐药（英文）

摘　　要：Ovarian cancer is one of the most lethal gynecologic cancers.The standard therapy for ovarian cancer has been the same for the past two decades,a combination treatment of platinum with paclitaxel.Recently,the FDA approved three new therapeutic drugs,two poly(ADP-ribose)polymerase inhibitors(olaparib and niraparib)and one vascular endothelial growth factor inhibitor(bevacizumab)as maintenance therapies for ovarian cancer.In this review,we summarize the resistance mechanisms for conventional platinum-based chemotherapy and for the newly FDA-approved drugs.

关 键 词：Drug resistance ovarian cancer CISPLATIN CARBOPLATIN PACLITAXEL OLAPARIB niraparib BEVACIZUMAB 

分 类 号：R73[医药卫生—肿瘤]